Haitao LYU, Dr

Professor Haitao Lyu, PhD., FRSC., FRSB

Dr. Haitao Lyu is an associate professor with tenure at School of Chinese Medicine, and a principal investigator at Institute for Research and Continuing Education in Hong Kong Baptist University, an elected fellow of The Royal Society of Chemistry, an elected fellow of The Royal Society of Biology, and an invited Faculty Member in Faculty Opinions (Faculty 1000 Prime). Between 2013 and 2023, Dr. Lyu was ever a professor with tenure at Shanghai Center for Systems Biology in Shanghai Jiao Tong University, a professor/assistant dean at School of Pharmaceutical Sciences in Chongqing University. Prior to undertake a postdoctoral training in Albert Einstein College of Medicine, Washington University School of Medicine, MIT SMART Center from 2009 to 2013, Dr. Lyu obtained bachelor’s degree in Chinese Materia Medica in 2004 and PhD degree in Pharmacognosy in 2009 from School of Pharmaceutical Sciences in Heilongjiang University of Chinese Medicine. Dr. Lyu’s group mostly concentrates on next-generation functional metabolomics for the interdisciplinary innovations of life and health sciences, and Dr. Lyu has secured more than 10 competitive grants from different funding agencies, such as National Natural Science Foundation of China, Ministry of Science and Technology of People’s Republic of China, Shanghai Bureau of Science and Technology of China, Agilent Technologies, etc. Dr. Lyu has published 58 authored and co-authored articles in many high profile journals. Dr. Lyu resumes the role of Editorial Board of many prestigious journals, including Pharmacological Research (Q1 TOP, IF 10.3, Section Editor), Phytomedicine (Q1 TOP, IF 6.5, Former Associate Editor), Royal Society Open Sciences (Q1, IF 3.6, Associate Editor), Proteomics (Q1, IF 5.3, EBM), and Acta Pharmaceutica Sinica B (Q1 Top, IF 14.3, EBM). Dr. Lyu is recipient of QUT Vice Chancellor Research Fellowship (2013), recipient of Agilent ACT-UR Award (2021), recipient of Faculty Opinions Member of The Year Award (2022), and recipient of Editorial Board Member of Excellence for Acta Pharmaceutica Sinica B (2022). 

EMPLOYMENT

Associate Professor with Tenure, PhD Candidate Supervisor

Division of Chinese Medicine Teaching and Research

School of Chinese Medicine

Hong Kong Baptist University, Hong Kong, China (April 2022 Effective )

Associate Professor with Tenure, PhD Candidate Supervisor

Faculty Director, Laboratory of Functional Metabolomics Science

Shanghai Center of Systems Biomedicine

Shanghai Jiao Tong University, Shanghai, China (July 2022-April 2023 )

Specialized-Appointment Professor, PhD Candidate Supervisor

Faculty Director, Laboratory of Functional Metabolomics Science

Shanghai Center of Systems Biomedicine

Shanghai Jiao Tong University, Shanghai, China (May 2016-April 2023 )

Elected Fellow (FRSC), The Royal Society of Chemistry in UK (2021-till now )

Elected Fellow (FRSB), The Royal Society of Biology in UK (2021-till now )

Faculty Member, Faculty Opinions (Faculty 1000 Prime) (2021-till now )

Adjunct Professor, PhD Candidate Supervisor, Systems Pharmacology

Macau University of Science and Technology, Macau, China (2020-till now)

Vice Chancellor’s Fellow, PhD Candidate Supervisor, Metabolomics

Institute of Health and Biomedical Innovation, Faculty of Health

Queensland University of Technology, Brisbane, Australia (2013-2016)

Professor, PhD Candidate Supervisor, Metabolomics and Chemical Biology

Faculty Director, Central Mass Spectrometry and Omics Facility

Chongqing University School of Pharmaceutical Sciences, Chongqing, China (2012-2016)

Postdoctoral Research Scientist, Metabolomics and RNA Modifications

SMART Research Centre, Department of Biological Engineering

Massachusetts Institute of Technology, Singapore and Cambridge, USA (2012-2012)

Postdoctoral Research Associate, Metabolomics and Microbiology

Department of Molecular Microbiology, Center for Women's' Infectious Diseases Research

Washington University School of Medicine, Saint Louis, USA (2010-2012)

Postdoctoral Research Fellow, Metabolomics and Metabolic Biology

Diabetes Research and Training Center, Department of Medicine

Albert Einstein College of Medicine, New York, USA (2009-2010)

AWARDS AND FELLOWSHIPS

2022 Recipient of Faculty Opinions Member of The Year Award

2022 Recipient of Editorial Board Member of Excellence for Acta Pharmaceutica Sinica B

2022 Elected Fellow (FLS), The Linnean Society of London in UK

2021 Elected Fellow (FRSC), The Royal Society of Chemistry in UK

2021 Elected Fellow (FRSB), The Royal Society of Biology in UK

2021 Faculty Member, Faculty Opinions Prime (Former F1000 Prime)

2021 Recipient of Agilent-Tech Global-Competitive ACT-UR Award

2015 Special Young Professorship Provided by SJTU

2013 ECARD/VCRF Travel Fellowships Provided by QUT

2013 The Vice Chancellor’ Research Fellowship Provided by QUT

2012 Young Hundred-Talent Professorship Provided by CQU

2012 Short-Term SMART Research Fellowships provided by MIT

2010 Postdoctoral Fellowship, Washington University School of Medicine

2010 American Association for the Advancement of Science (AAAS)/Science

Program for Excellence in Science, Sponsored Membership, USA

2009 Postdoctoral Fellowship, Albert Einstein College of Medicine, USA

2009 Achievement Award of Science and Technology, Ministry of Education,

P. R. China

EDITORIAL BOARD OF PEER-REVIEWED JOURNALS

2018-2021, Phytomedicine (Associate Editor)

Since 2020, Pharmacological Research (Section Editor)

Since 2022, Royal Society Open Science (Associate Editor)

Since 2019, Proteomics (EBM)

Since 2018, Acta Pharmaceutica Sinica B (Youth EBM)

PEER REVIEWER OF FUNDING AGENCY

Since 2013, National Natural Science Foundation of China

Since 2021, Health and Medical Research Fund (HMRF) in Hong Kong, China

Since 2016, National Health and Medical Research Council (NHMRC) in Australia

Selected Research Grant (PI)

13) Project title: STORM strategy innovated molecular diagnosis and therapeutic targets of

pancreatic cancer

Grant Number: NRCTM(SH)-2021-07

Funding Body: National Research Center for Translational Medicine (Shanghai, China)

Expected Period: 2022-2025

Total Funding: US $ 65,000.00

Role: Chief Investigator (Dr. Haitao Lu)

12) Project title: Investigating the mechanism of siderophore biosynthesis regulating

biofilm formation in Escherichia coli

Grant Number: 21ZR1431600

Funding Body: Shanghai Natural Science Foundation of China

Expected Period: 2021-2024

Total Funding: US $ 40,000.00

Role: Chief Investigator (Dr. Haitao Lu)

11) Project title: STORM strategy innovated therapeutic discovery of pancreatic cancer

Grant Number: 2021-2-4620

Funding Body: Agilent-Applications and Core Technology-University Research Fund

Expected Period: 2021-2022

Total Funding: US $ 35,000.00

Role: Chief Investigator (Dr. Haitao Lu)

10) Project title: Metabolic Phenotyping and Metabolically Modulatory Mechanisms of

Multiple-Organs Metastasis of Pancreatic Cancer

Grant Number: 2017YFC1038

Funding Body: National Key Projects for Research and Innovation of China

Expected Period: 2017-2021

Total Funding: US $ 600,000.00

Role: Chief Investigator (Dr. Haitao Lu)

9) Project title: Pathogenic Escherichia coli guided the discovery and characterization of

novel functional-secondary compounds

Grant Number: 31670031

Funding Body: National Natural Science Foundation of China

Expected Period: 2017-2020

Total Funding: US $ 120,000.00

Role: Chief Investigator (Dr. Haitao Lu)

8) Project title: Development and Applications of Precision-Modification Metabolomics

Grant Number: WF220441502

Funding Body: The Professorship Startup Grant provided by SJTU

Expected Period: 2016-2019

Total Funding: US $ 200,000.00

Role: Chief Investigator (Dr. Haitao Lu)

7) Project title: Discovery and functional characterization of novel siderophores

Grant Number: 106112015CDJZR468808

Funding Body: The Fundamental Research Funds for Then Central Universities Key Grant

Expected Period: 2015-2017

Total Funding: US $ 80,000.00

Role: Chief Investigator (Dr. Haitao Lu)

6) Project title: Metabolomics driven translational research of TCM, Panax Ginseng

against Type 2 Diabetes

Grant Number: CQDXWL-2014-Z002

Funding Body: The Fundamental Research Funds for The Central Universities

Expected Period: 2014-2017

Total Funding: US $ 60,000.00

Role: Chief Investigator (Dr. Haitao Lu)

5) Project title: Metabolomics identifies functional small molecules of Panax Ginseng

against Type 2 Diabetes

Grant Number: CSTC2014JCYIA10109

Funding Body: Natural Science Foundation of Chongqing in China

Expected Period: 2014-2017

Total Funding: US $ 10,000.00

Role: Chief Investigator (Dr. Haitao Lu)

4) Project title: Professional visit as an effort to build collaboration between QUT and

Chongqing University in China

Grant Number: ECARD/VCRF2013-2013

Funding Body: QUT ECARD/VCRF Travel Fellowship

Expected Period: 2013-2014

Total Funding: AU $ 7 K

Role: Chief Investigator (Dr. Haitao Lu)

3) Project title: Identification of key metabolite biomarkers and associated metabolic

pathways for monitoring musculoskeletal injury

Grant Number: 150410-0070/08

Funding Body: QUT Vice Chancellor Research Fellowship

Expected Period: 2013-2014

Total Funding: US $ 250,000.00

Role: Principal Investigator (Dr. Haitao Lu)

2) Project title: Metabolomics identifies bioactive components and associated therapeutic

mechanisms of Pyrrosla lingua (Thunb) at a metabolic level.

Grant Number: 81274175

Funding Body: National Natural Science Foundation of China

Expected Period: 2013-2016

Total Funding: US $ 150,000.00

Role: Chief Investigator (Dr. Haitao Lu)

1) Project title: Development of Integrated Omics Platform and its application to

translational research of the complex diseases

Grant Number: 0236011104401

Funding Body: Chongqing University “Young-100 Talents” Professorship Foundation

Expected Period: 2013-2016

Total Funding: US $ 300,000.00

Role: Principal Investigator (Dr. Haitao Lu)

Dr. Lyu’s Group has been mostly focusing on the method innovations and translational applications of functional metabolomics in the interdisciplinary sciences of life and health. The academic achievements of the candidate can be summarized as the follows: 1) definition and development of novel methods and strategies of functional metabolomics, such as precision-modification metabolomics and spatial temporal operative real metabolomics (STORM). 2) elucidation of the new regulatory-mechanism of siderophore biosynthesis on the virulence formation of pathogenic Escherichia coli; 3) clarification of novel mechanism of biofilm formation in pathogenic Escherichia coli at a functional-metabolism level, conserving novel strategy to tangle all the harmful impact of biofilms by targeting functional metabolites, which are extremely threaten-microorganisms mostly accounted for high-frequency drug resistance, air pollution and food contamination. 4) identification of novel metabolite biomarkers that can facilitate the diagnosis and metastasis monitoring of pancreatic cancer, as well as characterization of novel metabolic targets for disease therapy. Currently, Dr. Lyu’s Group further studies the novel methods of next-generation functional metabolomics (STORM+) aiming at promoting the interdisciplinary applications of life and health sciences by the discovery of poly-functional metabolites. 

Haitao Lu or Haitao Lv